Our Mission
Our mission is to identify novel therapeutics for life-threatening diseases that have no standard of care or lack effective therapy. We are dedicated to treating diseases with significant unmet needs by expanding the promise of precision medicine.
In 2019, we were the first-and-only global pharmaceutical company focused on the noncatalytic regulatory roles of aminoacyl-tRNA synthetases (ARSs) as novel therapeutic targets for the most challenging-to-treat diseases. Today, our pioneering efforts continue to show promise across a number of disease states and countless targets.
ZYMEDI is redefining how diseases are viewed from the perspective of ARS
All living organisms are operated, without exception, by the flow of genetic information to the production of protein through translation.
ARSs are responsible for charging amino acids to cognate tRNA molecules, which is the essential first step of protein translation. Beyond their catalytic roles, ARSs play additional noncatalytic activities for body homeostasis. Our goal is to harness the role of ARSs in human diseases, which has been overlooked for decades.
ARS is an overlooked target for drug development with limited studies targeting ARSs for infectious disease. With our deep understanding of ARS biology, we are transforming the role of ARS as a novel therapeutic target. By targeting the noncatalytic function of ARS, we are developing safer, multimodal novel therapeutics that meet the unmet needs in difficult diseases.
